Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 | 1 | GlobeNewswire (USA) | ||
ARTELO BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
03.03. | Artelo Biosciences GAAP EPS of -$3.05 | 1 | Seeking Alpha | ||
03.03. | Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results | 98 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop... ► Artikel lesen | |
03.03. | ARTELO BIOSCIENCES, INC. - 10-K, Annual Report | - | SEC Filings | ||
14.02. | Artelo Biosciences reports promising nonclinical CBD study | 1 | Investing.com | ||
14.02. | Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex | 1 | GlobeNewswire (USA) | ||
13.01. | Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 | 118 | GlobeNewswire (Europe) | The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan.... ► Artikel lesen | |
13.01. | EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Program | 2 | Benzinga.com | ||
20.12.24 | ARTELO BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
09.12.24 | Artelo meldet positive vorläufige Daten für Medikament gegen Krebs-Anorexie | 5 | Investing.com Deutsch | ||
09.12.24 | Artelo reports positive preliminary data for cancer anorexia drug | 1 | Investing.com | ||
09.12.24 | Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia | 3 | GlobeNewswire (USA) | ||
18.11.24 | Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit | 3 | GlobeNewswire (USA) | ||
13.11.24 | Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium | 135 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments... ► Artikel lesen | |
05.11.24 | Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's "Preclinical Screening Platform for Pain" Program | 3 | GlobeNewswire (USA) | ||
09.10.24 | Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th | 1 | GlobeNewswire (USA) | ||
13.08.24 | Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update | 119 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments... ► Artikel lesen | |
15.07.24 | Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor | 183 | GlobeNewswire (Europe) | ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected... ► Artikel lesen | |
29.05.24 | Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24 | 170 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments... ► Artikel lesen | |
23.04.24 | Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy | 182 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 84,20 | -1,17 % | Biontech-Partner unter Druck: Schwerer Vorwurf an Pfizer: War der Covid-Impfstoff viel früher ready? | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbIm Zentrum steht die Frage: Hat Pfizer die Bekanntgabe des Erfolgs seines gemeinsam mit... ► Artikel lesen | |
CUREVAC | 2,614 | -1,06 % | EQS-News: CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE
27.03.2025... ► Artikel lesen | |
QIAGEN | 37,435 | +1,42 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
AMGEN | 276,80 | -1,95 % | P/E Ratio Insights for Amgen | ||
NOVAVAX | 5,248 | -4,70 % | Novavax Aktie: Dunkelheit vor dem Sturm? | Der Biotechnologiekonzern verzeichnet erhebliche Kursverluste, setzt jedoch auf die Kooperation mit Sanofi als wichtigen Baustein für zukünftige Ertragsquellen und Kostenoptimierung. Die Novavax-Aktie... ► Artikel lesen | |
BIOGEN | 119,80 | -0,99 % | Biogen Says FDA Grants Fast Track Designation To BIIB080 For Treatment Of Alzheimers Disease | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,481 | -2,04 % | Palatin: Bremelanotide-Tirzepatide Combination Achieves Primary Endpoint In Phase 2 Obesity Study | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,430 | -5,92 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
MAINZ BIOMED | 5,695 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie
27.03.2025 / 14:01... ► Artikel lesen | |
BIONXT SOLUTIONS | 0,341 | -2,01 % | Novo Nordisk, BioNxt Solutions, Bayer Aktie: Drei Wege zu Gesundheit und Rendite | Die Pharmabranche boomt - und drei Unternehmen stehen 2025 besonders im Rampenlicht: Novo Nordisk, BioNxt Solutions und Bayer. Alle drei verbindet ein Ziel: Mit innovativen Ansätzen die Gesundheit von... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,120 | -6,63 % | Viking Therapeutics (NASDAQ:VKTX) Sets New 12-Month Low - Time to Sell? | ||
INTELLIA THERAPEUTICS | 6,340 | -5,85 % | Intellia Focuses on Pipeline Development Amid Stiff Competition | ||
COSCIENS BIOPHARMA | 2,720 | +2,26 % | COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer | ||
BIOCRYST PHARMACEUTICALS | 6,742 | -1,49 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 58,20 | +1,11 % | Sarepta upgraded at H.C. Wainwright on valuation, Q1 result expectation |